We are live on ! Find out more
OVID icon

Ovid Therapeutics

2.20 USD
-0.14
5.98%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
2.17
-0.03
1.36%
1 day
-5.98%
5 days
-12.7%
1 month
-6.78%
3 months
-19.71%
6 months
-7.95%
Year to date
25%
1 year
80.33%
5 years
-35.67%
10 years
-82.04%
 

About: Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Employees: 23

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
Seeking Alpha
4 days ago
Ovid Therapeutics Inc. (OVID) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
Ovid Therapeutics Inc. ( OVID ) UBS Global Biopharma Conference 2026 November 16, 2026 9:40 AM EST Company Participants Meg Alexander - CEO, President & Director Conference Call Participants Aidan Bracken Presentation Aidan Bracken Good afternoon, everyone. My name is Aidan Bracken.
Ovid Therapeutics Inc. (OVID) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
Neutral
GlobeNewsWire
10 days ago
Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results
OV329 is advancing in a global, Phase 2 focal epilepsy study expected to read out in H2 2027 Ovid is enrolling patients in ongoing photosensitivity study intended to demonstrate the anticonvulsant effect of OV329; results expected in early 2027 OV4071, the first-ever oral KCC2 direct activator, continues to progress in a Phase 1 single- and multiple-ascending dose study; translational ketamine challenge study ready for initiation Advancement of a pediatric formulation of OV329 is on track and Company plans to initiate a study in TSC-associated seizures before year-end 2026, representing the first indication in a broad potential DEE franchise Cash, cash equivalents and marketable securities were $161.4 million as of September 30, 2026; expected financial runway into 2029 NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the third quarter ended September 30, 2026. “The third quarter was focused on execution toward multiple, near-term clinical milestones across our pipeline,” said Meg Alexander, President and Chief Executive Officer.
Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results
Neutral
GlobeNewsWire
15 days ago
Ovid Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company's management will participate in three upcoming investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference – Tuesday, November 10 at 8:30 am ET Stifel 2026 Healthcare Conference – Wednesday, November 11 at 3:20 pm ET UBS European Healthcare Conference – Monday, November 16 at 2:40 pm GMT Webcasts of the presentations can be accessed through the Events & Presentations section of the company's website at  investors.ovidrx.com . An archived replay of the webcasts will be available on the Company's website following the live presentation for approximately 30 days.
Ovid Therapeutics to Participate in Upcoming Investor Conferences
Neutral
PRNewsWire
1 month ago
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of Matt David, M.D., as Chief Financial Officer.
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
Neutral
GlobeNewsWire
2 months ago
Ovid Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company's management will participate in two upcoming investor conferences: Cantor Global Healthcare Conference – Wednesday, September 9 at 2:10 pm ET H.C.
Ovid Therapeutics to Participate in Upcoming Investor Conferences
Positive
Zacks Investment Research
3 months ago
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
Neutral
Zacks Investment Research
3 months ago
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.06 per share a year ago.
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
Neutral
GlobeNewsWire
3 months ago
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the second quarter ended June 30, 2026.
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
Negative
Zacks Investment Research
3 months ago
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
Neutral
GlobeNewsWire
4 months ago
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced several strategic appointments strengthening its executive leadership team to support the Company's next phase of development.
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
Price charts implemented using Lightweight Charts™